Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
28804124
PubMed Central
PMC5668495
DOI
10.1038/leu.2017.253
PII: leu2017253
Knihovny.cz E-zdroje
- MeSH
- analýza přežití * MeSH
- antitumorózní látky terapeutické užití MeSH
- chronická myeloidní leukemie farmakoterapie terapie MeSH
- dospělí MeSH
- imatinib mesylát terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- transplantace hematopoetických kmenových buněk MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- antitumorózní látky MeSH
- imatinib mesylát MeSH
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.
1 Medizinische Klinik Klinikum Bremen Mitte Bremen Germany
2 Medizinische Klinik und Poliklinik Universitätsklinikum Schleswig Holstein Kiel Germany
2 Medizinische Klinik Universitätsklinikum Eppendorf Hamburg Germany
3 Medizinische Klinik Medizinische Fakultät Mannheim Universität Heidelberg Mannheim Germany
Ambulante Hämatologie und Onkologie Bonn Germany
Barmherzige Brüder Regensburg Germany
Caritas Krankenhaus Lebach Germany
Diakonie Schwäbisch Hall Germany
Hämatologische Onkologische Schwerpunktpraxis Würzburg Germany
IBE Universität München Munich Germany
Innere Medizin 1 Universitätsklinikum Freiburg Germany
Institut für Humangenetik MHH Hanover Germany
Internistische Schwerpunktpraxis Erlangen Germany
Kantonsspital Aarau Switzerland
Klinik 1 für Innere Medizin Universitätsklinikum Köln Germany
Klinik für Hämatologie und medizinische Onkologie Universitätsmedizin Göttingen Germany
Klinik für Innere Medizin 1 Universität des Saarlandes Homburg Germany
Klinik für Innere Medizin 2 Universitätsklinikum Jena Germany
Klinik für innere Medizin 3 Chemnitz Germany
Klinik für Innere Medizin 3 Universitätsklinikum Ulm Germany
Klinik für Innere Medizin 3 Westpfalz Klinikum Kaiserslautern Germany
Klinik für innere Medizin Universitätsklinikum Marburg Germany
Klinik für Knochenmarktransplantation Essen Germany
Klinik für Onkologie und Hämatologie Oldenburg Germany
Klinik und Poliklinik für Innere Medizin 3 Universitätsklinikum Regensburg Germany
Klinikum Schwabing Munich Germany
Masaryk University Hospital Brno Czech Republic
Medizinische Abteilung 2 Universitätsklinikum Tübingen Germany
Medizinische Klinik 2 Herford Germany
Medizinische Klinik 3 Städtisches Klinikum Karlsruhe Germany
Medizinische Klinik 3 Universität Bonn Germany
Medizinische Klinik 3 Universität München Munich Germany
Medizinische Klinik 5 Klinikum Nürnberg Nord Nürnberg Germany
Medizinische Klinik 5 Universität Heidelberg Heidelberg Germany
Medizinische Klinik 5 Universitätsklinikum Erlangen Germany
Medizinische Klinik A Universitätsklinikum Münster Germany
Medizinische Klinik und Poliklinik Universitätsklinikum Würzburg Germany
Onkologie Leer UnterEms Leer Germany
Onkologie Zentrum Ansbach Germany
Onkologische Schwerpunktpraxis Bielefeld Germany
Onkologische Schwerpunktpraxis Heilbronn Germany
Praxisklinik für Hämatologie und Onkologie Koblenz Germany
St Antonius Hospital Eschweiler Germany
St Marien Hospital Hagen Germany
St Marien Krankenhaus Siegen Germany
Stauferklinikum Schwäbisch Gmünd Mutlangen Germany
Zobrazit více v PubMed
O'Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004. PubMed
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017; 376: 917–927. PubMed PMC
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Mueller MC, Pletsch N et al. Tolerability-adapted imatinib 800mg/d versus 400mg/d versus 400mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634–1642. PubMed
Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096–2102. PubMed
Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood 2015; 126: 42–49. PubMed PMC
Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118: 6760–6768. PubMed
Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol 2015; 94: 2015–2024. PubMed
Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415–423. PubMed
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511–2521. PubMed
Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A et al. Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011; 118: 3228–3235. PubMed
Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E et al. Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009; 113: 4497–4504. PubMed
Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28: 424–430. PubMed PMC
Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol 2014; 99: 616–624. PubMed
Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E et al. Imatinib 800mg daily induces deeper molecular responses than imatinib 400mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 2014; 164: 223–232. PubMed PMC
Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600mg/day of imatinib as initial therapy. Blood 2008; 112: 3965–3973. PubMed
Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 2015; 125: 915–923. PubMed PMC
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C et al. Final 5-Year Study Results of DASISION: The Dasatinib versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 2016; 34: 2333–2340. PubMed PMC
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044–1054. PubMed PMC
Gratwohl A, Pfirrmann M, Zander A, Kroger N, Beelen D, Novotny J et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia 2016; 30: 562–569. PubMed PMC
Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820. PubMed
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872–884. PubMed PMC
Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858. PubMed
Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016; 30: 48–56. PubMed
Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172–2175. PubMed
Branford S, Fletcher L, Cross NCP, Müller MC, Hochhaus A, Kim D-W et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330–3338. PubMed
Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118: 1208–1215. PubMed
Dupont WD. PS power and sample size program available for free on the internet. Controlled Clin Trial 1997; 18: 274.
Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38: 163–170. PubMed
Shkolnikov V, Barbieri M, Wilmoth J. The Human Mortality Databasehttp://www.mortality.org/.
Pfirrmann M, Lauseker M, Hoffmann VS, Hasford J. Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death. Ann Hematol 2015; 94: S209–S218. PubMed
Pfirrmann M, Hochhaus A, Lauseker M, Sausele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 2011; 25: 1433–1438. PubMed
Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141–1154.
Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710–719. PubMed
Pohar M, Stare J. Relative survival analysis in R. Comput Methods Programs Biomed 2006; 81: 272–278. PubMed
Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–799. PubMed
Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686–692. PubMed
Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A et al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol 2014; 140: 1965–1969. PubMed
Kalmanti L, Saussele S, Lauseker M, Muller MC, Dietz CT, Heinrich L et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 29: 1123–1132. PubMed
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 2016; 17: 612–621. PubMed
Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029–1035. PubMed
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia